KORU Medical Systems, Inc. (KRMD) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-03-12
Business type: Asset play
How it makes money
It earns by selling infusion hardware and consumables to distributors who supply patients requiring long-term subcutaneous immunoglobulin therapy.
Revenue is generated through the sale of syringe drivers, specialized tubing, and safety needles. The primary profit drivers are the volume of consumables sold to patients managing chronic immune deficiencies and the success of partnerships with biopharmaceutical companies to tailor the system for new drug launches.
What protects it: the moat
It relies on regulatory clearances and specialized product adoption to maintain its market position.
The company claims a leadership position in large-volume subcutaneous infusion. However, it concedes that its competitive moat depends on continuous innovation, successful clinical integration with drug manufacturers, and the complex process of securing and maintaining regulatory approvals.
What growth costs
It reinvests heavily in research and development and sales infrastructure to secure clinical partnerships and geographic expansion.
Growth requires constant investment in technical innovation to customize devices for emerging drugs and expanded sales commissions to drive market penetration. The company does not detail specific maintenance versus growth capital expenditure, but confirms that substantial resources are necessary to keep pace with technological advances.
What could damage it
The loss of its few major distributors would immediately impair its ability to reach end customers.
Because 77% of net revenues depend on only nine distributors, a shift in their purchasing behavior or a termination of these commercial relationships would cause an immediate and significant contraction in sales that cannot be easily replaced.
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.